Crovalimab - CISMeF

Preferred Label : Crovalimab;

NCIt definition : A humanized recycling monoclonal antibody directed against the complement pathway protein C5, with potential complement pathway inhibitory and immunomodulating activities. Upon administration, crovalimab targets and binds to a specific C5 epitope, thereby preventing C5 convertase-mediated cleavage of C5, inhibiting the formation of C5a and C5b, and the C5b6 deposition on membranes. This inhibits C5-mediated signal transduction, the formation of the membrane attack complex (MAC) and the activation of the terminal complement pathway. This results in the prevention and/or inhibition of both complement-mediated inflammation and cell destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). C5 plays a key role in the activation of the complement cascade. Crovalimab is engineered with sequential monoclonal antibody recycling technology (SMART).;

UNII : H9KH1GP3UU;

CAS number : 1917321-26-6;

Molecule name : RO7112689; SKY59;

NCI Metathesaurus CUI : CL1382222;

Details

Origin ID

C169867;

UMLS CUI

C5418336;

Currated CISMeF NLP mapping
- Crovalimab [SMS substance]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- crovalimab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
has_target
- Complement C5 [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients